Recombinant Factor X with no glycosylation and method for preparing the same
View Patent ↗A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.
1. A recombinant Factor X with inhibited glycosylation, wherein the recombinant Factor X is obtained by a process comprising inhibiting glycosylation by substituting alanine for asparagine at position 181 (N181A) of SEQ ID NO: 1.
2. A composition comprising:
the recombinant Factor X according to claim 1 ; and
a physiologically acceptable excipient.
3. A method of treating hemophilia, wherein the method comprises administering to a subject in need thereof an effective amount of the composition according to claim 2 .
4. A recombinant Factor X with inhibited glycosylation, wherein the recombinant Factor X is obtained by a process comprising inhibiting glycosylation by substituting alanine for asparagine at position 181 (N181A) and position 191 (N191A) of SEQ ID NO: 1.
5. A composition comprising:
the recombinant Factor X according to claim 4 ; and
a physiologically acceptable excipient.
6. A method of treating hemophilia, wherein the method comprises administering to a subject in need thereof an effective amount of the composition according to claim 5 .
7. A recombinant Factor X with inhibited glycosylation, wherein the recombinant Factor X is obtained by a process comprising inhibiting glycosylation by substituting alanine for threonine at position 159 (T159A) of SEQ ID NO: 1.
8. A composition comprising:
the recombinant Factor X according to claim 7 ; and
a physiologically acceptable excipient.
9. A method of treating hemophilia, wherein the method comprises administering to a subject in need thereof an effective amount of the composition according to claim 8 .
10. A recombinant Factor X with inhibited glycosylation, wherein the recombinant Factor X is obtained by a process comprising inhibiting glycosylation by substituting alanine for threonine at position 443 (T443A) of SEQ ID NO: 1.
11. A composition comprising:
the recombinant Factor X according to claim 10 ; and
a physiologically acceptable excipient.
12. A method of treating hemophilia, wherein the method comprises administering to a subject in need thereof an effective amount of the composition according to claim 11 .
13. A recombinant Factor X with inhibited glycosylation, wherein the recombinant Factor X is obtained by a process comprising inhibiting glycosylation by substituting alanine for threonine at position 159 (T159A) and position 443 (T443A) of SEQ ID NO: 1.
14. A composition comprising:
the recombinant Factor X according to claim 13 ; and
a physiologically acceptable excipient.
15. A method of treating hemophilia, wherein the method comprises administering to a subject in need thereof an effective amount of the composition according to claim 14 .
16. A recombinant Factor X with inhibited glycosylation, wherein the recombinant Factor X is obtained by a process comprising inhibiting glycosylation by substituting alanine for asparagine at position 181 (N181A) and position 191 (N191A) of SEQ ID NO: 1, and substituting alanine for threonine at position 159 (T159A) and position 443 (T443A) of SEQ ID NO: 1.
17. A composition comprising:
the recombinant Factor X according to claim 16 ; and
a physiologically acceptable excipient.
18. A method of treating hemophilia, wherein the method comprises administering to a subject in need thereof an effective amount of the composition according to claim 17 .